Elanco Animal Health Inc (ELAN) stock
ELANNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30129% above fair value
$26.70+0.85 (+3.29%)
Close on Nov 18, 2026Market cap $13.34BP/E –Yield –
Elanco Animal Health revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Elanco Animal Health's revenue for the twelve months ending Jun 30, 2026 was $5.02B, up 12.0% year over year. For fiscal 2025 it was $4.72B, up 6.2% from the year before. The highest annual figure on record is $4.76B in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.72B | +6.2% |
| FY2024 | Dec 31, 2024 | $4.44B | +0.5% |
| FY2023 | Dec 31, 2023 | $4.42B | +0.1% |
| FY2022 | Dec 31, 2022 | $4.41B | -7.4% |
| FY2021 | Dec 31, 2021 | $4.76B | +45.6% |
| FY2020 | Dec 31, 2020 | $3.27B | +6.5% |
| FY2019 | Dec 31, 2019 | $3.07B | +0.1% |
| FY2018 | Dec 31, 2018 | $3.07B | +6.2% |
| FY2017 | Dec 31, 2017 | $2.89B | -0.8% |
| FY2016 | Dec 31, 2016 | $2.91B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.37B | +10.2% |
| Q1 FY2026 | Mar 31, 2026 | $1.37B | +14.9% |
| Q4 FY2025 | Dec 31, 2025 | $1.14B | +12.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.14B | +10.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.24B | +4.8% |
| Q1 FY2025 | Mar 31, 2025 | $1.19B | -1.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.02B | -1.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.03B | -3.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.18B | +12.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.21B | -4.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.04B | +5.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.07B | +4.1% |
| Q2 FY2023 | Jun 30, 2023 | $1.06B | -10.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.26B | +2.5% |
| Q4 FY2022 | Dec 31, 2022 | $985.00M | -11.4% |
| Q3 FY2022 | Sep 30, 2022 | $1.03B | -9.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.18B | -8.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.23B | -1.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.11B | -2.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.13B | +27.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.28B | +118.1% |
| Q1 FY2021 | Mar 31, 2021 | $1.24B | +88.9% |
| Q4 FY2020 | Dec 31, 2020 | $1.14B | +44.8% |
| Q3 FY2020 | Sep 30, 2020 | $890.00M | +15.4% |
| Q2 FY2020 | Jun 30, 2020 | $586.00M | -25.0% |
| Q1 FY2020 | Mar 31, 2020 | $658.00M | -10.0% |
| Q4 FY2019 | Dec 31, 2019 | $787.00M | -1.5% |
| Q3 FY2019 | Sep 30, 2019 | $771.30M | +1.3% |
| Q2 FY2019 | Jun 30, 2019 | $781.60M | +1.5% |
| Q1 FY2019 | Mar 31, 2019 | $731.10M | -0.7% |
| Q4 FY2018 | Dec 31, 2018 | $799.30M | +6.0% |
| Q3 FY2018 | Sep 30, 2018 | $761.10M | +9.2% |
| Q2 FY2018 | Jun 30, 2018 | $770.20M | +5.1% |
| Q1 FY2018 | Mar 31, 2018 | $736.20M | +4.5% |
| Q4 FY2017 | Dec 31, 2017 | $754.30M | – |
| Q3 FY2017 | Sep 30, 2017 | $697.10M | – |
| Q2 FY2017 | Jun 30, 2017 | $732.80M | – |
| Q1 FY2017 | Mar 31, 2017 | $704.80M | – |
See a number that looks wrong?